Designated as a state-level center in 2012,Pharmaceutical R&D Center is considered one of the leading national enterprise technology centers of Pharmaceutical R&D in China. It mainly engaged anti-tumor drugs, cardiovascular drugs, antiviral drugs, anti-inflammatory drugs, and antibiotics drugs research.

   The center concentrates on university-industry cooperation and has established relations in subject research,project cooperation, personnel training with University of Science and Technology of China ,Fudan University, Beijing Institute of Technology , The Second Military Medical University, China Medical University, HeFei University of Technology ,Chinese Academy of Medical Sciences, Shanghai Institute of Pharmaceutical Industry, Tianjin Institute of Pharmaceutical Research , Institute of Microbiology, Chinese Academy of Sciences.

   In recent years, the center has developed and put into the production of category I state new drugs such as propranolol, naftopidil,category II state new drugs Zaleplon, Cinidipine,category II state new drugs Ibutilide fumarate filled the blank of this field, take the lead in developing exclusively new accessoriestriethyl citrate in China, to create a good economic and social benefits for BBCA Pharmaceutical. The center has declared more than 300 various kinds of invention patents, and nearly 100 invention patents have been obtained.